New combo shows promise for Tough-to-Treat myeloma
NCT ID NCT01745640
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of pomalidomide and dexamethasone in 63 patients with multiple myeloma that had returned or stopped responding to treatment, and who had specific high-risk genetic changes. The goal was to see how well the drugs controlled the disease and what side effects occurred. The results help doctors understand if this treatment can slow cancer growth in this difficult-to-treat group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pomalidomide and dexamethasone
What this could lead to
If successful, this combination could offer a treatment option for multiple myeloma patients with high-risk genetic features who have few alternatives.
What could go wrong
This is a small, early-phase study (63 patients) without a comparison group. Results may not apply to all patients, and side effects like low blood counts or infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU POITIERS-Hôpital Jean Bernard
Poitiers, 86021, France
-
CHRU RENNES 1, Hôpital Sud
Rennes, 35056, France
-
CHRU RENNES 2, Hôpital Pontchaillou
Rennes, 35033, France
-
CHRU, Hôpital A.Michallon
Grenoble, 38043, France
-
CHRU, Hôpital Purpan
Toulouse, 31059, France
-
CHRU, Hôpitaux de Brabois
Vandœuvre-lès-Nancy, 54511, France
-
CHRU, Hôtel Dieu
Nantes, 44035, France
-
CHRU- Hôpital Bretonneau
Tours, 37044, France
-
CHRU-Hôpital Sud Amiens
Amiens, 80054, France
-
CHU - Hôpital St Antoine,
Paris, 75571, France
-
CHU DIJON, Hôpital d'Enfants
Dijon, 21000, France
-
Centre Hospitalier Lyon Sud -1
Pierre-Bénite, 69495, France
-
Centre Hospitalier Lyon Sud -2
Pierre-Bénite, 69495, France
-
Centre hospitalier départemental La Roche sur Yon
La Roche-sur-Yon, 85025, France
-
Chru Caen
Caen, 14033, France
-
Chru Lille
Lille, 59037, France
-
Hôpital Haut-Leveque
Pessac, 33604, France
-
Hôpital Robert Debré, CHU Reims
Reims, 51092, France
-
Hôpital Saint-Louis
Paris, 75475, France
-
Institut Paoli Calmette,
Marseille, 13273, France